A new study is the first to demonstrate that chemotherapy and a new, targeted therapy work better in combination than chemotherapy alone in treating patients with the most common genetic subtype of lung cancer. The study was carried out by an international team of investigators led by Dana-Farber Cancer Institute scientists.
Published online today in iThe Lancet Oncology/i, the combination of chemotherapy and the targeted drug selumetinib was more effective than chemotherapy alone in a ...
A new study is the first to demonstrate that chemotherapy and a new, targeted therapy work better in combination than chemotherapy alone in treating patients with the most common genetic subtype of lung cancer. The study was carried out by an international team of investigators led by Dana-Farber Cancer Institute scientists.
Published online today in iThe Lancet Oncology/i, the combination of chemotherapy and the targeted drug selumetinib was more effective than chemotherapy alone in a ...